Sino Biopharmaceutical Limited is set to attend the 2025 European Hematology Association (EHA) Congress where they will present the preclinical and Phase Ib clinical data on rovadicitinib for the treatment of acute graft-versus-host disease (aGVHD). The results indicate an overall response rate of 84.6% at 28 days, with a 12-month overall survival rate of 92.3%.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.